Germline mutations in BRCA1 and BRCA2 genes in ethnically diverse high risk families in Israel
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Yael Laitman Roni Tsipora Borsthein Dominique Stoppa-Lyonnet Efrat Dagan Laurent Castera Maud Goislard Ruth Gershoni-Baruch Hadassah Gol
- چاپ و سال / کشور: 2010
Description
Three mutations in BRCA1 (185delAG, 5382InsC) and BRCA2 (6174delT) predominate among high risk breast ovarian cancer Ashkenazi Jewish families, with few ‘‘private’’ mutations described. Additionally, the spectrum of BRCA1 and BRCA2 germline mutations among high risk Jewish non Ashkenazi and non Jewish Israelis is undetermined. Genotyping by exon-specific sequencing or heteroduplex analysis using enhanced mismatch mutation analysis was applied to 250 high risk, predominantly cancer affected, unrelated Israeli women of Ashkenazi (n = 72), non Ashkenazi (n = 90), Moslem (n = 45), Christian Arabs (n = 21), Druze (n = 17), and non Jewish Caucasians (n = 5). All Jewish women were prescreened and did not harbor any of the predominant BRCA1 or BRCA2 Jewish mutations. Age at diagnosis of breast cancer (median ± SD) (n = 219) was 40.1 ± 11.7, 45.6 ± 10.7, 38.7 ± 9.2, 45.5 ± 11.4 ± and 40.7 ± 8.1 years for Ashkenazi, non Ashkenazi, Moslem, Christian, and Druze participants, respectively. For ovarian cancer (n = 19) the mean ages were 45.75 ± 8.2, 57.9 ± 10.1, 54 ± 8, 70 ± 0, and 72 ± 0 for these origins, respectively. Overall, 22 (8.8%) participants carried 19 clearly pathogenic mutations—10 BRCA1 and 9 BRCA2 (3 novel): 3 in Ashkenazim, 6 in 8 non- Ashkenazim, 6 in 7 Moslems, 2 in Druze, and 2 in non Jewish Caucasians. Only three mutations (c.1991del4, C61G, A1708E) were detected in 2 seemingly unrelated families of Moslem and non- Ashkenazi origins. There were no inactivating mutations among 55 Ashkenazi high risk breast cancer only families. In conclusion, there are no predominant recurring germline mutations in BRCA1 or BRCA2 genes among ethnically diverse Jewish and non Jewish high risk families in Israel.
Breast Cancer Res Treat (2011) 127:489–495 DOI 10.1007/s10549-010-1217-0 Received: 3 October 2010 / Accepted: 5 October 2010 / Published online: 20 October 2010 Springer Science+Business Media, LLC. 2010
